Mar 7, 2022 · Here, we report that Flonoltinib Maleate (FM), a selective JAK2/FLT3 inhibitor, shows high selectivity for JAK2 over the JAK family. Surface plasmon resonance assays …

Apr 1, 2017 · Our findings show that mutated FLT3-ITD and JAK2 augment ROS production and HR, shifting the cellular milieu toward illegitimate recombination events such as iHR and CN …

Apr 2, 2017 · We demonstrate here that mutant FLT3 and JAK2 confer augmented ROS species that induce DNA damage, resulting in both mutations and chromosomal instability as observed …

Apr 14, 2023 · Polypharmacological targeting of FLT3, JAK2, ABL, and MAPK signaling provides a durable response in AML. Despite significant advancements in developing selective FMS …

Our data strongly argues for the combined inhibition of FLT3 and JAK2 in FLT3-ITD-positive patients in two scenarios: as a first-line therapy to minimize the development of secondary …

Oral administration of pacritinib in murine models of FLT3-ITD-driven AML led to significant inhibition of primary tumor growth and lung metastasis. Upregulation of JAK2 in FLT3-TKI …

Nov 15, 2022 · We have previously developed a novel JAK2/FLT3 inhibitor, flonoltinib, and proved its better efficacy and safety than ruxolitinib in treating myeloproliferative neoplasm. This study …

Mar 7, 2022 · Here, we report that Flonoltinib Maleate (FM), a selective JAK2/FLT3 inhibitor, shows high selectivity for JAK2 over the JAK family. Surface plasmon resonance assays …

Nov 16, 2007 · We have developed TG101348, a selective JAK2/FLT3 small molecule inhibitor which has the potential to treat both MPDs and AML. In in vitro based assays, TG101348 was …

Nov 11, 2011 · Upregulation of JAK2 in FLT3-TKI-resistant AML cells was identified as a potential mechanism of resistance to selective FLT3 inhibition. This resistance could be overcome by …